Bruns Ingmar sold ZNTL
February 9, 2026 · Form 4 insider transaction
Bruns Ingmar sold 335 shares of Zentalis Pharmaceuticals, Inc. at $2.39 per share, a transaction worth $801.62. The trade was recorded as open-market sale and disclosed on an SEC Form 4, filed 1 day after the transaction.
Direction
Disposed (sell-side)
Shares
335
Price
$2.39
Total value
$801.62
InsiderBruns Ingmar
Role—
SecurityCommon Stock
Transaction codeS: Open-market sale
Transaction dateFebruary 9, 2026
Filing dateFebruary 10, 2026
Shares owned after33,332
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.